Research
Hormonal
Metformin, a widely used antidiabetic drug, activates AMPK indirectly by inhibiting mitochondrial complex I, which lowers cellular energy status and thereby activates the AMPK pathway.
Metformin, a common diabetes medication, works by slightly inhibiting your mitochondria's energy production. This small drop in energy triggers your AMPK sensor, which improves your body's ability to manage blood sugar and burn fat. It essentially tricks your body into thinking it is in a low-energy state, promoting metabolic health.
StrongSupportsVERY_HIGH confidence
Consistent with this, two of the major classes of drug currently widely used to treat Type 2 diabetes, i.e. biguanides like metformin... and the thiazolidinediones... have been reported to activate AMPK. Both appear to do this indirectly by inhibiting complex I of the respiratory chain...
Why this rating
Cites multiple studies confirming the mechanism in mice deficient in LKB1.
Source
AMP‐activated protein kinase – development of the energy sensor concept
D. Grahame Hardie et al. · The Journal of Physiology · 2006
DOI 10.1113/jphysiol.2006.108944
narrative_reviewCited 807×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- AMP-activated protein kinase (AMPK) acts as a cellular energy sensor that is activated by metabolic stresses (such as hypoxia, hypoglycemia, or muscle contraction) which increase the AMP:ATP ratio, subsequently switching on catabolic pathways to generate ATP while inhibiting biosynthetic pathways that consume ATP.Strong
- Exercise activates AMPK in skeletal muscle through mechanisms involving both LKB1-dependent (energy stress) and LKB1-independent (calcium-dependent) pathways, with the degree of activation depending on the intensity and type of exercise relative to the individual's fitness level.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →